DrugPatentWatch Database Preview

Cipla Company Profile

« Back to Dashboard

What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?

CIPLA has eighty-seven approved drugs.

There are four US patents protecting CIPLA drugs. There are thirty-one tentative approvals on CIPLA drugs.

There are twenty-three patent family members on CIPLA drugs in twenty-one countries and three hundred and two supplementary protection certificates in fifteen countries.

Summary for Cipla

International Patents:	23
US Patents:	4
Tradenames:	77
Ingredients:	77
NDAs:	87
Patent Litigation for Cipla:	See patent lawsuits for Cipla
PTAB Cases with Cipla as petitioner:	See PTAB cases with Cipla as petitioner

Drugs and US Patents for Cipla

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla Ltd	GRANISETRON HYDROCHLORIDE	granisetron hydrochloride	INJECTABLE;INJECTION	078262-001	Dec 31, 2007	AP	RX	No	No
Cipla	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	078171-003	Dec 13, 2013	AN	RX	No	No
Cipla	LAMIVUDINE	lamivudine	TABLET;ORAL	077221-002	Mar 3, 2017	AB	RX	No	No
Cipla Ltd	ZIDOVUDINE	zidovudine	SYRUP;ORAL	077981-001	Jun 26, 2008	AA	RX	No	No
Cipla Ltd	EPIRUBICIN HYDROCHLORIDE	epirubicin hydrochloride	INJECTABLE;INJECTION	065361-001	Oct 22, 2007	AP	RX	No	No
Cipla	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	200626-002	Aug 9, 2018	AB	RX	No	No
Cipla	PRAVASTATIN SODIUM	pravastatin sodium	TABLET;ORAL	077904-002	Oct 23, 2006	AB	RX	No	No

International Patents for Cipla Drugs

Country	Patent Number	Estimated Expiration
Japan	2011219498
Taiwan	I425947
Lithuania	2217610
China	103360440
South Korea	20100110297
Brazil	PI0819319
Mexico	2010005632

Supplementary Protection Certificates for Cipla Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0321122	2/1997	Austria		PRODUCT NAME: TOPOTECAN; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 EU/1/96/027/002 19961112; FIRST REGISTRATION: LI 53857 01 19961016
0502314	SPC/GB02/037	United Kingdom		PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0582455	C300032	Netherlands		PRODUCT NAME: EFAVIRENZ; REGISTRATION NO/DATE: EU/1/99/110/001-004, EU/1/99/111/001-004 19990528
2487163	93353	Luxembourg		PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE D'ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025
2487166	122016000104	Germany		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
1663240	CA 2016 00063	Denmark		PRODUCT NAME: RILPIVIRINHYDROCHLORID OG TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623
0481754	C300241	Netherlands		PRODUCT NAME: ENTECAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT, IN HET BIJZONDER ENTECAVIRMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/06/343/001-EU/1/06/343/005 20060626

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cipla
• Cipla Ltd
• Cipla Usa